News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alvine Pharmaceuticals, Inc. Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease



10/29/2013 10:04:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN CARLOS, Calif.--(BUSINESS WIRE)--Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, today announced that the first randomized study patient was dosed in the CeliAction Study™, a phase 2b study of its lead clinical candidate, ALV003, which is in development for the treatment of patients with celiac disease. ALV003 is an orally administered mixture of two gluten-specific proteases shown in vitro to degrade gluten, the primary immunologic trigger for celiac disease.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES